Abstract
Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, including midostaurin, enasidenib, ivosidenib, gemtuzumab–ozogamicin, and CPX351 by the US Food and Drug Administration has widened the treatment options for clinicians treating AML. This review focuses on some of these novel therapies and other promising agents under development, along with key clinical trial findings in AML.
Acknowledgments
PB (IA/S/15/1/501842) and VM (IA/S/11/2500267) are supported by Wellcome DBT India Alliance Senior fellowships. This study was partly funded by a Centre of Excellence grant from the Department of Biotechnology India (BT/COE/34/SP13432/2015).
Disclosure
SD is supported by a junior research fellowship from the University Grants Commission (UGC), New Delhi, India. The authors report no other conflicts of interest in this work.